# FDA WARNING_LETTER - Veronvy - December 17, 2024

Source: https://www.keypedia.com/records/warning_letter/veronvy/dd763f60-ffbe-4b5a-91c8-f256f04f918e

> FDA WARNING_LETTER for Veronvy on December 17, 2024. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Veronvy
- Inspection Date: 2024-12-17
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: The FDA issued a Warning Letter to Veronvy on December 10, 2024, following an October 2024 review of their website, veronvy.com. The letter addresses the sale of "Elily Veronvy" and "Elily Veronvy 40+" products in the U.S.

The FDA determined these products are unapproved new drugs, violating sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 355(a) and 331(d)). This is based on claims on Veronvy's website, such as "Veronvy Metabolic Boost Drops successfully helped people lose up to 52 pounds in 3 months during clinical trials and was approved by the Food and Drug Administration last year," and statements about appetite suppression, slowed gastric emptying, and accelerated metabolism for weight management. These claims establish the products' intended use as drugs, yet no FDA-approved applications exist.

Furthermore, the products are deemed misbranded under section 502(a) of the FD&C Act (21 U.S.C. 352(a)), violating section 301(a) (21 U.S.C. 331(a)). The website misleadingly displays an "FDA APPROVED" image and states the product "was approved by the Food

## Related Officers

- [Director](https://www.keypedia.com/people/tina-smith/5d590654-a270-4f3f-833f-d6fe13ca8c05)

Company: https://www.keypedia.com/companies/veronvy/51e87e72-3988-483b-8d97-e54b81fc402f

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c